In short
This article discusses the ongoing clinical trials investigating the use of Citric Acid, Anhydrous Ph. Eur., a component of the experimental drug VS-01, in treating acute-on-chronic liver failure (ACLF). The research focuses on patients with ACLF grades 1 and 2 who also experience ascites, a condition where fluid accumulates in the abdominal cavity. The trials aim to evaluate the efficacy, safety, and tolerability of VS-01 when administered alongside standard care, compared to standard care alone.
At a glance
- Drug Name
- VS-01 (containing Citric Acid, Anhydrous Ph. Eur.)
- Condition Studied
- Acute-on-chronic liver failure (ACLF) grades 1 and 2 with ascites
- Trial Phase
- Phase 2a proof of concept study
- Administration Method
- Intraperitoneal (i.p.) daily for 4 days
- Primary Endpoint
- CLIF-C ACLF score at Day 7
- Key Secondary Endpoints
- Mortality rates, time to ACLF resolution, transplant-free survival
- Patient Population
- Adults 18-79 years with liver cirrhosis and ACLF grade 1 or 2
- Study Duration
- 90 days (4-day treatment period + follow-up)
- Comparison
- VS-01 + Standard of Care vs. Standard of Care alone
What is VS-01?
VS-01 is a new medicinal product being studied for the treatment of a serious liver condition called acute-on-chronic liver failure (ACLF) in patients who also have ascites. It is a suspension for infusion, which means it's a liquid medication that is given through a special route in your body.
The active ingredient in VS-01 is citric acid, anhydrous. While citric acid is commonly known as a substance found in citrus fruits, in this medication it's being used in a purified form for medical purposes.
What conditions does VS-01 treat?
VS-01 is designed to treat acute-on-chronic liver failure (ACLF). Let's break down what this means:
- Chronic liver failure: This is long-term liver damage, often due to conditions like cirrhosis.
- Acute-on-chronic liver failure (ACLF): This occurs when a person with chronic liver disease experiences a sudden worsening of their condition. It can lead to the failure of multiple organs and is very serious.
- Ascites: This is a buildup of fluid in the abdomen, which is common in people with severe liver disease.
ACLF is particularly dangerous, with a mortality rate of about 50%. It can cause problems with brain function (a condition called hepatic encephalopathy) and the buildup of toxic substances in the body.
How VS-01 works
While the exact mechanism isn't fully explained in the trial information, VS-01 is administered intraperitoneally. This means it's given directly into the abdominal cavity where the excess fluid (ascites) has accumulated.
The medication is given daily for 4 days, suggesting it may help to remove toxins or reduce inflammation in the abdominal area. This could potentially help improve liver function and reduce the severity of ACLF.
Clinical Trial Information
VS-01 is currently being studied in a Phase 2a clinical trial. This is an early stage of testing in humans to see if the medication is effective and safe. The study is described as a "proof of concept" trial, which means it's designed to see if the treatment shows promise and should be studied further.
The trial is comparing VS-01 plus standard care to standard care alone. This helps researchers understand if VS-01 provides additional benefits beyond current treatments.
Who can participate in the VS-01 trial?
The trial is looking for adult patients (ages 18-79) who have:
- Liver cirrhosis (scarring of the liver)
- ACLF grade 1 or 2 (specific levels of liver failure)
- Ascites that requires drainage
- Developed ACLF within the last 7 days
There are many other specific criteria for who can and cannot participate. Your doctor would need to review these in detail to determine if you might be eligible.
Potential Benefits and Risks
Potential benefits of VS-01, if proven effective, could include:
- Improved liver function
- Reduced severity of ACLF
- Better survival rates for patients with this serious condition
However, as with any experimental treatment, there may be risks and side effects that are not yet known. The trial is designed to carefully monitor patients for any adverse reactions.
It's important to remember that VS-01 is still in the testing phase. More research is needed to determine its effectiveness and safety before it could become widely available as a treatment.